
Opinion|Videos|September 23, 2024
Managing Severe Symptoms and Disease Progression in the GVHD Journey
Panelists discuss how chronic graft-versus-host disease typically progresses in patients requiring third-line treatment and beyond, focusing on severe symptoms, the impact on quality of life, and potential long-term consequences of inadequately managed symptoms.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you describe the typical disease course for cGVHD patients, particularly those who progress to third-line treatment and beyond? What are some of the most severe symptoms they face?
- How does the burden of cGVHD impact a patient's quality of life, and what are some of the long-term consequences if symptoms are not properly managed?
Advertisement
Related to this article

In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.

In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.

Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.

Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.

At ASTRO 2026, Suresh Rana details how AI-driven contouring accelerates care timelines, requiring rigorous team monitoring and early nursing input.

At ASTRO 2026, Dr. Erica Braschi Jordan details toxicity tracking, physical therapy referral, and quality of life in proton regional nodal irradiation.

At ASTRO 2026, Dr. Mishaal Munir details how nurse-led triage workflows and prompt symptom escalations improve care for breast cancer brain metastases.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Anktiva Plus BCG: Telling Expected Immune Effects From Red Flags
2
Automated Breast Ultrasound Tied to Fewer False-Positives in Dense Breasts
3
Future Directions in Metastatic Triple-Negative Breast Cancer Care
4
Delaying BSO to Age 50 Leaves BRCA1 Carriers With 24% Ovarian Cancer Risk
5

